Aeglea BioTherapeutics to Present at BIO Digital 2020
June 01 2020 - 4:05PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare and other high-burden
diseases, today announced it will provide a corporate overview at
BIO Digital being held virtually June 8-12, 2020.
Presentation Details
Date: June 8-12, 2020 Presenter: Anthony G. Quinn,
M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: https://www.bio.org/events/bio-digital
The presentation will be available for download on the
Presentations & Events section of the Company’s website and
also will be available on-demand to registered participants of BIO
Digital at
https://www.bio.org/events/bio-digital/sessions/620997.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designations. The
Company received approval of its Clinical Trial Application (CTA)
for ACN00177 for the treatment of Homocystinuria by the United
Kingdom’s Medicines and Healthcare Products Regulatory Agency
(MHRA). Aeglea has an active discovery platform, with the most
advanced program for Cystinuria. For more information, please visit
http://aegleabio.com.
Media Contact:Kelly Boothe, Ph.D.Director,
Corporate CommunicationsAeglea BioTherapeutics 512.399.5458
media@aegleabio.com
Investor Contact:Joey PerroneSenior Director,
Finance & Investor RelationsAeglea
BioTherapeuticsinvestors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Apr 2023 to Apr 2024